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Abstract
Huntingtin, the protein that when mutated causes Huntington disease (HD), has many known
interactors and participates in diverse cellular functions. Mutant Htt (mHtt) engages in a variety of
aberrant interactions that lead to pathological gain of toxic functions as well as loss of normal
functions. The broad symptomatology of HD, including diminished voluntary motor control,
cognitive decline, and psychiatric disturbances, reflects the multifaceted neuropathology.
Although currently available therapies for HD focus on symptom management, the autosomal
dominant cause and the adult onset make this disease an ideal candidate for genetic intervention. A
variety of gene therapy approaches have been tested in mouse models of HD, ranging from those
aimed at ameliorating downstream pathology or replacing lost neuronal populations to more
upstream strategies to reduce mHtt levels. Here the authors review the results of these preclinical
trials.
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Huntington disease (HD) is caused by the expansion of a polyglutamine (polyQ) tract in
exon 1 of the multifunctional protein Htt. Affected individuals have more than 36 glutamine
repeats, and longer polyQ tracts correlate with earlier onset and increased disease severity
(Huntington’s Disease Collaborative Research Group 1993). Expanded polyQ Htt induces
degeneration and eventual loss of susceptible neuronal populations in the striatum and
cortex. Chief among these are striatal medium spiny neurons (MSNs), whose population
undergoes an early and severe loss. The deficit in neurons and their processes results in a
dramatic atrophy of the putamen and caudate nucleus, as well as cortical thinning (Rosas
and others 2008). HD usually presents in midlife with chorea, dementia, and weight loss,
with death typically occurring 15 to 20 years after symptom onset (Walker 2007). Although
the appearance of gross motor deficits or dementia is commonly referred to as disease onset,
carriers of expanded polyQ in HD can display psychiatric symptoms such as anxiety,
depression and obsessive compulsive disorder, mild cognitive impairments of episodic
memory and executive function, and fine motor deficits years to decades before defined
clinical onset (Biglan and others 2009; Duff and others 2007). Elevated levels of
proinflammatory cytokines are also present in serum at least 16 years prior to motor
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symptom onset, reflecting the role of inflammation in this disease (Bjorkqvist and others
2008).
The simple genetic nature and autosomal dominant transmission of HD should facilitate
therapy development. Unlike multicause, predominately idiopathic neurodegenerative
diseases such as Alzheimer and Parkinson diseases, identification of premanifest mutation
carriers and thus presymptomatic treatment initiation is possible for HD. This allows for
neuroprotective strategies rather than more complicated restorative methods or techniques
for coping with existing neuronal loss. Nonetheless, the therapies currently available to HD
patients, which include selective serotonin reuptake inhibitors (SSRIs) and atypical
antipsychotics for psychiatric disturbances and tetrabenazine for chorea, offer only moderate
symptom relief and have no effect on disease progression (De Marchi and others 2001;
Huntington Study Group 2006).
In striking contrast to the simplicity of HD genetics, the convoluted disease mechanisms in
this disorder have hindered development of disease-modifying therapies. The Htt protein is a
large, promiscuous protein that is known to associate with many molecular partners,
including proteins, DNA, and mRNA, as well as cellular components that include the
endoplasmic reticulum (ER), mitochondria, microtubules, the plasma membrane, and
endocytic, synaptic, and autophagic vesicles (Imarisio and others 2008). Wild-type Htt
(wtHtt) is a jack of all trades, playing roles in numerous, seemingly unrelated processes that
include transcriptional regulation, apoptosis suppression, ER stress signaling, calcium
homeostasis, axonal transport, endocytosis, and synaptic transmission (Zuccato and others
2010). In HD, mHtt fails to adequately perform these essential roles and also acquires toxic
functions related to accumulation, aggregation, and sequestration of essential proteins, as
well as aberrant interactions. This combination of loss and gain of function creates a
network of cellular dysfunction that leads to impaired proteolysis, transcriptional regulation,
intracellular trafficking, mitochondrial metabolism, calcium signaling, and synaptic activity
(Imarisio and others 2008; Ramaswamy, Shannon, and others 2007). Consequently, there is
a wide variety of potential HD therapeutic targets—from the mHtt protein itself to myriad
downstream factors, many of which have been evaluated for gene therapy efficacy in mouse
models of HD.
Downstream Targets
Neurotrophic Factor Delivery
Neurotrophic factors are secreted growth factors that can enhance differentiation, function,
and survival of neurons. Ectopic expression of neurotrophic factors mediated either by viral
vectors or the transplantation of genetically modified cells has shown some promise in the
treatment of mouse models of HD.
Nerve growth factor (NGF) is the prototypical neurotrophin that not only promotes neuronal
survival but can also down-regulate Htt expression in cultured striatal neurons (Haque and
Isacson 2000). NGF delivery by transplantation of transfected neural stem cells (NSCs) is
neuroprotective when administered prior to injection of quinolinic acid (QA), an N-methyl-
D-aspartate (NMDA) receptor agonist that induces excitotoxicity and neuropathology similar
to that found in HD (Martinez-Serrano and Bjorklund 1996). Transplantation of
mesenchymal stem cells (MSCs) genetically engineered to overexpress NGF into the
striatum of four-month-old YAC128 mice (a transgenic model expressing full-length mHtt)
results in moderate improvements in rotarod and clasping behavior but no increase in striatal
neuron number or expression of dopamine and cyclic-AMP-regulated phosphoprotein
(DARPP-32), a marker of healthy MSNs (Dey and others 2010).
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Brain-derived neurotrophic factor (BDNF), which is required for differentiation and survival
of striatal MSNs, is reduced in the human HD striatum. Expression of BDNF is activated by
wtHtt, a function that is lost with polyQ expansion (Zuccato and Cattaneo 2007). Viral
delivery of BDNF to the striatum of rats prior to injection of QA is neuroprotective,
resulting in reduced cell loss and lesion volume (Bemelmans and others 1999; Kells and
others 2004). Astrocytes cultured from transgenic mice expressing BDNF driven by the glial
fibrillary acid protein (GFAP), astrocyte-specific promoter, increase their BDNF production
in response to inflammatory insults. When grafted into the striatum of nude mice one week
or one month before QA injection, these cells produce excess BDNF, which reduces lesion
volume and prevents neuronal death, as measured by NeuN, a marker of neuronal nuclei.
This neuroprotection is selective, resulting in increased DARPP-32-positive MSNs and
parvalbumin-positive but not choline acetyltransferase–positive interneurons. In addition,
BDNF-expressing astrocyte grafts in unilaterally lesioned animals decrease apomorphine-
induced rotation, indicating that function is preserved in the protected neurons (Giralt and
others 2010). The beneficial effects of ectopic BDNF expression have also been
demonstrated in the YAC128 transgenic model of HD. In four-month-old mice, striatal
injection of MSCs harvested from mouse femurs and transfected to produce BDNF results in
improved clasping and rotarod performance. At 13 months of age, BDNF-MSC-grafted mice
have displayed more NeuN- and DARPP-32-positive striatal neurons than unmodified MSC-
grafted or vehicle-injected mice, illustrating the long-term benefit of this treatment (Dey and
others 2010).
Cilliary neurotrophic factor (CNTF), a member of the interleukin (IL)–6 or neuropoietic
cytokine family, promotes the survival of a broad range of neuronal types, including those
most susceptible to mHtt-induced toxicity (Ip and Yancopoulos 1996). Although
neuroprotective in QA rat models of HD (De Almeida and others 2001; Emerich and others
1996; Régulier and others 2002), CNTF has shown no benefit and, in some cases, a
detriment in HD transgenic mice. Lentiviral delivery of CNTF into YAC72 mice results in
excellent striatal expression for up to one year following surgery. Although no exacerbation
of behavioral deficits is found in treated animals, reduced DARPP-32 expression and NeuN-
positive cells as well as increased GFAP expression are seen in the striatum of both wild-
type and YAC72-treated mice (Zala and others 2004). Moreover, adeno-associated virus
(AAV) delivery of CNTF into the striatum of 10-week-old R6/1 mice results in earlier onset
of rotarod deficits. In addition, this treatment increases body weight loss and reduces
expression of striatally enriched genes such as DARPP-32 and preproenkephalin in both
transgenic and wild-type mice (Denovan-Wright and others 2008). These studies indicate
that long-term overexpression of CNTF is not well tolerated, and therefore this neurotrophic
factor is not a good candidate for gene therapy in HD.
Glial cell line–derived neurotrophic factor (GDNF) is produced in the developing striatum
and is expressed by adult striatal projection neurons as well as interneurons (Pérez-Navarro
and others 2000). Viral- and cell-mediated delivery of GDNF prior to QA injection is
neuroprotective in rats (Kells and others 2004; Pérez-Navarro and others 1999; Pérez-
Navarro and others 1996). Transplantation of NSCs transfected to produce GDNF protects
against QA toxicity in nude mice, resulting in moderately reduced loss of NeuN-positive
striatal neurons and reduced amphetamine-induced rotation (Pineda and others 2006). When
given after symptom onset, lentiviral delivery of GDNF to four- to five-week-old R6/2 mice
has no effect on rotarod, clasping, or open field behavior. Intranuclear inclusions, BrdU
staining, and neuronal cross-sectional area are also unaffected in these animals (Popovic and
others 2005). However, presymptomatic AAV-GDNF delivery to five-week-old N171-82Q
transgenic mice significantly delays onset of clasping and rotarod deficits. At 16 weeks of
age, compared with untreated mice, the striata of treated mice have decreased inclusions and
increased neuronal number with larger cross-sectional areas, although striatal volume loss is
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not improved (McBride and others 2006). Moreover, transplantation of GDNF-secreting
mouse neural progenitor cells (NPCs) into 60-day-old N171-82Q mice following symptom
onset results in delayed body weight loss and dramatic improvement in rotarod performance.
GDNF-NPC transplantation also results in reduced inclusions and increased NeuN-positive
cells in the striatum but no improvement in cortical thinning. Although some loss of tyrosine
hydroxylase is seen in areas proximal to the graft, no loss of dopaminergic neurons is
observed (Ebert and others 2010). Thus, GDNF can be a restorative as well as a preventative
treatment.
Neuturin (Ntn), a member of the GDNF family, promotes survival of projection neurons that
mediate hypo-kinetic movement, making it a logical candidate for the treatment of HD, a
disease characterized by hyperkinetic movement (Alberch and others 2002). Cell-mediated
delivery of Ntn protects projection neurons but not interneurons in QA-lesioned rat striata,
which is the opposite effect seen with GDNF overexpression (Pérez-Navarro and others
2000). This indicates that although these neurotrophins share expression patterns and
receptor family members, they have differential mechanisms of action. As MSNs, the most
susceptible neurons in HD, are projection neurons, Ntn may be more suitable for HD gene
therapy than GDNF. Viral-mediated delivery of Ntn into rats treated with the mitochondrial
toxin 3-NP is neuroprotective and ameliorates motor deficits (Ramaswamy, McBride, and
others 2007). AAV delivery of Ntn to the striatum of six-week-old N171-82Q mice results
in increased stride length and delayed rotarod deficits and clasping compared to AAV-GFP-
or vehicle-treated transgenic mice. Treatment with AAV-Ntn dramatically increases striatal
neuron as well as layer 5 and 6 cortical neuron numbers. This therapy, however, has no
effect on neuronal cross-sectional area, inclusion deposition, or mouse survival
(Ramaswamy and others 2008). Interestingly, inclusion deposition and neuronal cross-
sectional area are measures that are improved by GDNF treatment, indicating that there may
be increased benefit of combining these very promising neurotrophic factor gene therapies.
Activation of Endogenous Neural Stem Cells
One approach to coping with neuronal loss is the activation of endogenous NSCs in the adult
brain. One site of NSCs throughout life is within the subventricular zone (Taupin and Gage
2002). Delivery of adenoviral-BDNF (AdB) into the subventricular zone results in increased
NSC proliferation and migration of newly formed cells into the striatum, although the
majority of these cells differentiate into glia. Coexpression of noggin, an inhibitor of
gliogenesis, pushes these newly generated cells toward a neuronal fate. Intraventricular
delivery of BDNF and noggin (AdB/N) into R6/2 mice increases neurogenesis, leading to
recruitment of new striatal MSNs, which project axons to their targets. AdB/N gene therapy
also results in improved rotarod performance and increased spontaneous activity as well as a
17% increase in survival time (Cho and others 2007). It is remarkable that the new neurons
“know where to go and what to do when they get there.” Because BDNF can stimulate the
generation of several other types of neurons, it seems that the local environment in the
damaged striatum contains the cues necessary for MSN differentiation.
Normalization of Calcium Signaling and Mitochondrial Function
Mitochondrial dysfunction in HD, which includes altered respiration, membrane potential,
and metabolism, leads to disruption of calcium homeostasis, excess production of reactive
oxygen species, and excitotoxicity (Damiano and others 2010). One of the ways that the
mHtt protein induces energy dysregulation is by repressing transcription of PGC-1α, a
regulator of mitochondrial metabolism. Lentiviral delivery of PGC-1α into the striatum of
R6/2 mice completely prevents loss of individual neuronal volumes, supporting
mitochondrial involvement in HD-related neurodegeneration (Cui and others 2006).
Mitochondria from HD patient–derived lymphocytes display reduced calcium-buffering
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capacity, leading to excess cytosolic calcium (Panov and others 2002). This causes
excitotoxicity and aberrant calcium signaling. Calmodulin (CaM), a regulatory protein that
associates with mHtt, activates a number of enzymes upon calcium binding. Among these is
transglutaminase, an enzyme that catalyzes covalent cross-linking of glutamine residues and
possibly contributes to mHtt-induced toxicity. Intrastriatal, AAV-mediated delivery of a
CaM fragment to R6/2 mice disrupts mHtt-CaM interaction, leading to a reduction in the
level of transglutaminase-modified mHtt. AAV-CaM gene therapy also improves rotarod
performance, gait, and hypoactivity, as well as deposition of inclusions and loss of neuronal
size and body weight, although mouse survival is unaffected (Dai and others 2009). It will
be of interest to determine the effects of this form of gene therapy in full-length models of
HD.
Targeting mHtt
Increased Clearance
Considering the multiplicity of pathogenic mechanisms of HD, a more comprehensive,
upstream therapeutic approach is to reduce mHtt protein levels by increasing its degradation.
Removal of mHtt is less likely to have deleterious off-target effects and more likely to
ameliorate all aspects of the HD phenotype than are therapies directed at downstream
dysfunctions. Interventions that selectively reduce levels of mHtt while sparing the wt
protein are preferable because long-term reduction of wtHtt may not be well tolerated. As
mentioned at the outset, wtHtt protein is important for neuronal health throughout life, and
mice with wtHtt conditionally knocked out in adulthood develop progressive motor
impairment and neuropathology (Dragatsis and others 2000). Small-molecule-mediated
increases in mHtt clearance have been unsuccessful thus far, ostensibly because of the
elaborate and somewhat mysterious mechanisms of endogenous mHtt degradation. On the
other hand, gene therapy approaches to selectively increase mHtt clearance have shown
considerable promise.
One such approach uses viral-mediated delivery of intrabodies (iAbs), which are
intracellularly expressed Ab fragments that recognize and bind Htt in living cells. Several
anti-Htt iAbs have been developed as potential therapeutics, and the most promising of these
reduce mHtt-induced toxicity by promoting its degradation. EM48 is an iAb that recognizes
an epitope in the C-terminus of HDx1. Although this epitope is common to mutant and
wtHtt, EM48 preferentially binds mHtt on Western blots, possibly because of polyQ
expansion–induced conformational changes. Observations in a cellular model of HD reveal
that EM48 binding increases the ubiquitination and subsequent degradation of mHtt.
Intrastriatal Ad delivery of this iAb into R6/2 and N171-82Q mouse models results in
increased Htt cleavage and reduced neuropil aggregates, demonstrating in vivo efficacy of
EM48-enhanced mHtt degradation. EM48-treated N171-82Q mice also display improved
gait and rotarod performance. However, EM48 gene therapy does not prevent loss of body
weight or enhance the survival of these animals (Wang C-E and others 2008).
Another iAb, Happ1, binds the proline-rich region of Htt adjacent to the polyQ tract. Despite
its recognition of wtHtt under denaturing conditions, Happ1 binding selectively increases
the turnover of mutant but not wtHtt in cellular models of HD (Southwell and others 2008).
This iAb-induced turnover involves enhanced calpain cleavage of mHtt (Southwell and
others 2011). The target epitope of Happ1 is the site of multiple endogenous protein-protein
interactions, which are enhanced by polyQ expansion, suggesting increased epitope
availability in the context of mHtt (Passani and others 2000; Qin and others 2004; Steffan
and others 2000). This is likely to be responsible for the selectivity of Happ1 action under
native conditions. Intrastriatal AAV delivery of Happ1 is beneficial in five different mouse
models of HD. In a unilateral, acute lentiviral-mHtt mouse model, Happ1 treatment prevents
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the amphetamine-induced rotation phenotype and reduces striatal lesion size and intensity as
well as mHtt aggregation. In genetic HD models, Happ1 treatment improves rotarod and
beam-crossing performance of R6/2, N171-82Q, YAC128, and BACHD mice and
spontaneous climbing in YAC128 and BACHD mice. Happ1 treatment also normalizes
open-field exploration in YAC128 and BACHD mice and object learning in YAC128 mice,
demonstrating benefit in the psychiatric and cognitive dimensions of the HD-like phenotype.
An object learning deficit in BACHD mice is unchanged by Happ1 treatment, however.
Happ1 treatment also improves neuropathological measures, including ventricular
enlargement in R6/2, YAC128, and BACHD mice and inclusion load in R6/2. Importantly,
Happ1 gene therapy increases body weight and increases life span by 30% in the N171-82Q
model (Fig. 1), although there is no benefit of Happ1 treatment in these outcomes in the
more severe and earlier onset R6/2 model (Southwell and others 2009).
The ability of anti-Htt iAbs to increase clearance of mHtt and subsequent therapeutic benefit
can be improved by fusion to targeting sequences, which direct the degradation of the bound
Htt-iAb complex. The iAb C4, which recognizes the N-terminus of HDx-1, reduces mHtt-
induced toxicity and aggregation in cell culture, brain slice, and fly models of HD (Lecerf
and others 2001; Murphy and Messer 2004; Wolfgang and others 2005), but AAV-mediated
C4 gene therapy in R6/1 HD model mice confers only modest phenotypic benefit (Snyder-
Keller, McLear and others 2010). A fusion protein of this iAb and a PEST signal sequence, a
peptide rich in proline, glutamic acid, serine, and threonine, efficiently targets mHtt for
proteasomal degradation. C4-PEST significantly reduces levels of both soluble and insoluble
mHtt in cotransfected cultured striatal cells (Snyder-Keller, Butler and others 2010). It will
be interesting to see how this modification affects C4 gene therapy efficacy in HD mice.
A different strategy for reducing mHtt levels involves induction of autophagy. Autophagy is
a lysosomal degradation process for long-lived and misfolded cytoplasmic proteins that can
selectively degrade mHtt (Sarkar and Rubinsztein 2008). Chemical induction of autophagy
results in accelerated clearance of mHtt and subsequent therapeutic benefit in fly and mouse
HD models (Ravikumar and others 2004; Rose and others 2010; Sarkar and others 2008).
Drug-mediated global induction of autophagy, however, is not specific to Htt and could
potentially have off-target effects, particularly over the extremely long treatment duration
required for HD therapy. The lack of understanding of the regulation of endogenous,
autophagy-mediated mHtt degradation hampers selective drug development, and therefore
there is interest in gene therapy approaches. Specific targeting of mHtt for autophagic
degradation has been demonstrated in the R6/2 mouse model by intrastriatal AAV-mediated
delivery of an expanded polyQ binding peptide (QBP1), which binds mutant but not wtHtt.
This peptide is fused to a synthetic HSC70 chaperone-binding motif (HSC70bm), which
targets bound proteins to lysosomes for degradation. Artificial, chaperone-mediated,
autophagic degradation of mHtt in these animals results in reduced levels of both aggregated
and soluble mHtt protein in brain lysates and inclusions in transduced striata. QBP1-
HSC70bm gene therapy improves clasping and rotarod performance and reduces striatal
atrophy. This promising therapy also improves body weight and dramatically increases the
survival of this very severe model (Bauer and others 2010). One would like to see this
approach tested in a full-length mHtt model.
Silencing
The most upstream and direct strategy for the treatment of HD is silencing expression of
mHtt mRNA, thus preventing generation of the toxic protein and all subsequent pathology.
At least 10 RNAi gene therapy efficacy preclinical trials have been performed since 2005,
using a variety of rodent models of HD. These studies, recently reviewed by Harper (2009),
are briefly summarized here.
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Intrastriatal AAV delivery of a short hairpin RNA (shRNA), HDsh2.1, in N171-82Q mice
results in reduced inclusions and improved rotarod performance and gait but no change in
loss of body weight (Harper and others 2005). Another shRNA, siHUNT-1, which targets
the 5′UTR of Htt, delivered by AAV into the striatum of R6/1 mice, reduces inclusions and
moderately improves clasping behavior and transcriptional dysregulation but not loss of
body weight (Rodriguez-Lebron and others 2005). Postsymptomatic onset, intrastriatal AAV
delivery of an shRNA in the HD190QG mouse model causes reduction of inclusion load and
a modest restoration of DARPP-32 expression (Machida and others 2006). In an AAV-
generated mouse model of HD, intrastriatal co-injection of mHtt plus cholesterol-conjugated
small interfering RNA (siRNA), cc-siRNA-Htt, reduces inclusions, improves clasping and
beam-crossing performance, and ameliorates neuronal loss but not neuronal shrinkage
(DiFiglia and others 2007). Adenoviral delivery of an shRNA targeting HDx-1 in the
striatum of R6/2 mice as well as an Ad-HDx-1 model of HD reduces transgene expression
and inclusions (Huang and others 2007). Co-delivery of an shRNA, AAV-shHD2, along
with AAV-HDx-1, ameliorates loss of NeuN- and calbindin-positive cells in the striatum of
rats and normalizes asymmetric forepaw use in unilaterally injected animals (Franich and
others 2008). The most positive results to date involve intraventricular delivery of a
cholesterol-conjugated siRNA targeting HDx-1 in neonatal R6/2 mice, resulting in reduced
mHDx-1 expression. Compared to control-treated mice, those receiving the HDx-1-siRNA
display reduced inclusions, delayed clasping and loss of body weight, improved rotarod
performance and spontaneous activity, reduced striatal atrophy, and an increase in longevity
of 14% (Wang Y-L and others 2005).
Taken together, the RNAi results appear very promising. An important caveat of these
studies is, however, that they have all employed species-specific RNAi reagents that only
target human Htt. As a result, endogenous mouse Htt is not silenced, although it would be in
comparable human HD applications. Some studies have found that nonspecific Htt silencing
is relatively nontoxic in mice, resulting in gene expression changes but no overt behavioral
phenotype (Boudreau and others 2009; Drouet and others 2009; McBride and others 2008).
Nonspecific silencing has in fact been shown to confer therapeutic benefit in a transgenic
mouse model of HD. AAV-mediated delivery of miRNA2.4 into the striatum of seven-
week-old N171-82Q mice results in a 75% reduction of both human transgene and mouse
endogenous Htt mRNAs. Compared to AAV-GFP- and vehicle-treated mice, miRNA-
treated mice display improved rotarod performance and a trend toward increased survival
but no change in loss of body weight (Boudreau and others 2009). This suggests that
nonspecific Htt silencing would be a viable therapeutic option for human HD. The
prolonged treatment duration required in humans and the general resistance to Htt-associated
neurodegeneration in the mouse brain should be considered, however. If sensitivity to Htt-
associated neuropathology were similar between mice and humans, heterozygous knock-in
HD mice with polyQ lengths equivalent to those seen in patients would model human HD
fairly closely. In actuality, these mice have no clear HD-related phenotype (White and others
1997), and to model human HD in mice, polyQ expansion lengths well above those seen in
humans are used, often in the context of a highly toxic N-terminal fragment. For these
reasons, allele-specific mHtt gene silencing that does not disrupt wtHtt expression will be
preferable for therapeutic applications.
As the HD-causing mutation is an expansion of a normally occurring sequence, development
of allele-specific silencing reagents has required ingenuity. Peptide and locked nucleic acid
oligonucleotides targeting expanded CAG have shown modest success in selective mHtt
silencing in cellular models of HD, although selectivity of these reagents declines in the
absence of a large repeat length difference between the normal and mutant allele (Hu and
others 2009). Nonetheless, the extremely focused therapeutic mechanism and the potential
benefit to not only those afflicted with HD but to those with other CAG expansion diseases
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warrants further development and optimization of expanded CAG-targeting
oligonucleotides. Allele-specific mHtt silencing could also be accomplished by targeting
single-nucleotide polymorphisms (SNPs). Many SNPs that are enriched in expanded polyQ
human Htt genes have been identified, and silencing reagents targeting a small number of
these disease-associated SNPs could provide a therapeutic option for the majority of HD
patients (Lombardi and others 2009; Pfister and others 2009; Warby and others 2009).
Development of silencing reagents targeting these SNPs is currently under way, and gene
therapy efficacy trials in rodent models of HD are eagerly expected in the near future.
Perspectives
It is apparent that a wide variety of gene therapy approaches display promise for prevention
as well as treatment of HD symptoms. Several of these approaches also have potential
application in other polyQ diseases, as well as in other neurodegenerative diseases that
involve protein misfolding, such as Parkinson and Alzheimer diseases and the prionoses.
What are the next steps toward human trials? In some cases, the gene therapies must be
tested in full-length HD models. In other cases, the reagents must be optimized for use in
humans. There is some debate as to the steps after that. One possibility is to test the reagents
in animals with larger brains so as to optimize delivery of the vectors (Ciron and others
2009; Fiandaca and others 2009; Varenika and others 2009). Another possibility is to test the
therapies for efficacy in nonhuman primates. This could be done using lentiviral delivery of
mHtt (Palfi and others 2007). There are also genetic HD models being developed using
monkeys, pigs, and sheep (Jacobsen and others 2010; Yang D and others 2010; Yang S-H
and others 2008). It will also be extremely important to develop inducible viral vectors so
that a transgene that turns out to be ineffective or harmful can be turned off.
Apart from the experimental hurdles that must be overcome, there is a psychological barrier
unique to gene therapy in the brain that needs to be confronted. Many researchers believe
that inserting genes into the brain is too dangerous and so only small-molecule approaches
should be developed. This view reflects a widespread lack of awareness of the many gene
therapy trials that are already ongoing or have been concluded in humans. These include
trials of potential treatments for Parkinson and Alzheimer diseases as well as others
(Christine and others 2009; Kaplitt and others 2007; Mandel 2010; Marks and others 2008).
In general, such trials have shown that the safety of the surgery and vector delivery is not a
cause for great concern, although new methods are still under development. There is also the
issue of side effects; direct delivery of vectors into the brain avoids peripheral side effects,
and gene therapies with high target specificity (as with iAbs, for instance) may avoid
potential side effects of delivering small-molecule reagents to the periphery.
A daunting reality is that most of the therapies developed in mouse models of cancer, for
instance, fail in human trials. For that reason alone, it is important that the wide variety of
gene therapy approaches summarized here proceed in parallel toward human testing.
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Figure 1.
Happ1 gene therapy improves body weight of N171-82Q Huntington disease (HD) model
mice. The green fluorescent protein (GFP)–treated N171-82Q mouse (left) displays reduced
body weight, hunched posture, and piloerection (ruffled coat), whereas the Happ1-treated
N171-82Q mouse (right) displays normal body weight and appearance. The mice shown are
male littermates.
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ct
or
; G
D
N
F 
= 
gl
ia
l c
el
l l
in
e–
de
riv
ed
 n
eu
ro
tro
ph
ic
 fa
ct
or
; H
D
 =
H
un
tin
gt
on
 d
is
ea
se
; I
C
V
 =
 in
tra
ce
re
br
ov
en
tri
cu
la
r; 
IS
 =
 in
tra
st
ria
ta
l; 
M
SN
 =
 m
ed
iu
m
 sp
in
y 
ne
ur
on
; N
D
 =
 n
ot
 d
et
er
m
in
ed
; N
PC
 =
 n
eu
ra
l p
ro
ge
ni
to
r c
el
l; 
O
F 
= 
op
en
-f
ie
ld
 e
xp
lo
ra
tio
n;
 O
L 
= 
ob
je
ct
 le
ar
ni
ng
;
R
R
 =
 ro
ta
ro
d;
 S
A
 =
 sp
on
ta
ne
ou
s a
ct
iv
ity
; s
iR
N
A
 =
 sm
al
l i
nt
er
fe
rin
g 
R
N
A
; V
E 
= 
ve
nt
ric
ul
ar
 e
nl
ar
ge
m
en
t.
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